Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success
Also Sees Chance To Challenge Hemlibra
Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: big pharma and Ukraine; new gene therapy deal for Novartis; Phase III hemophilia success for Sanofi; J&J’s Gorsky’s views on Asia innovation; and a look at pharma’s deal-making activity last year.
The company is aiming for an outcomes-based payment model in the US, while it is confident the gene therapy will fare better than some others have in Europe.
New data show fitusiran’s promise across hemophilia A and B, but a switch to a lower dose prompted by safety concerns will delay its filing until 2024.